CT303

GENETIC2 trials

Sponsors

GC Cell Corporation

Conditions

Acute Respiratory Distress SyndromeModerate to Severe Plaque Psoriasis

Phase 1

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS

WithdrawnNCT05238532

GC Cell CorporationAcute Respiratory Distress Syndrome

Start: 2022-01-26End: 2023-02-22Updated: 2023-04-04

Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With Psoriasis

GC Cell CorporationModerate to Severe Plaque Psoriasis

Start: 2021-10-25End: 2024-12-30Target: 24Updated: 2022-03-18